It’s Official: FDA Approval Does Not Equal CMS Coverage
This article was originally published in RPM Report
Executive Summary
Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.
You may also be interested in...
Straight Talk About Cancer Drug Coverage
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.